Signaling Mechanisms of Vav3, a Guanine Nucleotide Exchange Factor and Androgen Receptor Coactivator, in Physiology and Prostate Cancer Progression

作者: Leah S. Lyons , Kerry L. Burnstein

DOI: 10.1007/978-1-4614-6828-8_6

关键词: Androgen receptorTyrosine phosphorylationCancer researchVAV3Prostate cancerNuclear receptor coactivator 2GTPaseNuclear receptor coactivator 3Guanine nucleotide exchange factorBiology

摘要: The Rho GTPase guanine nucleotide exchange factor (GEF) Vav3 is the third member of Vav family GEFS and activated by tyrosine phosphorylation. Through stimulation activity, promotes cell migration, invasion, other cellular processes. Work from our laboratory first established that upregulated in models castration-resistant prostate cancer progression enhances androgen receptor as well splice variant activity. Recent analysis clinical specimens supports a potential biomarker aggressive cancer. Consistent with role promoting castration-­resistant disease, versatile enhancer both ligand-dependent ligand-independent mechanisms such impacts pathways reactivation advanced Distinct domains participate -independent coactivation. To provide physiologic context, we review actions elucidated gene knockout studies. This chapter describes pervasive to castration resistance. We discuss which cells exploit signaling promote activity under different hormonal milieus, are relevant Lastly, data on emerging for cancers ranging leukemias gliomas.

参考文章(89)
Rute B. Marques, Natasja F. Dits, Sigrun Erkens-Schulze, Wilfred F. J. van IJcken, Wytske M. van Weerden, Guido Jenster, Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines PLoS ONE. ,vol. 6, pp. e23144- ,(2011) , 10.1371/JOURNAL.PONE.0023144
Victor LJ Tybulewicz, Vav-family proteins in T-cell signalling. Current Opinion in Immunology. ,vol. 17, pp. 267- 274 ,(2005) , 10.1016/J.COI.2005.04.003
Martin Houlard, Ramachandran Arudchandran, Fabienne Regnier-Ricard, Antonia Germani, Sylvie Gisselbrecht, Ulrich Blank, Juan Rivera, Nadine Varin-Blank, Vav1 is a component of transcriptionally active complexes. Journal of Experimental Medicine. ,vol. 195, pp. 1115- 1127 ,(2002) , 10.1084/JEM.20011701
Xosé R Bustelo, Vav proteins, adaptors and cell signaling. Oncogene. ,vol. 20, pp. 6372- 6381 ,(2001) , 10.1038/SJ.ONC.1204780
Jeff Holzbeierlein, Priti Lal, Eva LaTulippe, Alex Smith, Jaya Satagopan, Liying Zhang, Charles Ryan, Steve Smith, Howard Scher, Peter Scardino, Victor Reuter, William L. Gerald, Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance American Journal of Pathology. ,vol. 164, pp. 217- 227 ,(2004) , 10.1016/S0002-9440(10)63112-4
Simon Haile, Marianne D. Sadar, Androgen receptor and its splice variants in prostate cancer Cellular and Molecular Life Sciences. ,vol. 68, pp. 3971- 3981 ,(2011) , 10.1007/S00018-011-0766-7
Karen E Knudsen, Trevor M Penning, None, Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer Trends in Endocrinology and Metabolism. ,vol. 21, pp. 315- 324 ,(2010) , 10.1016/J.TEM.2010.01.002
Vincent Sauzeau, María A Sevilla, Juan V Rivas-Elena, Enrique de Álava, María J Montero, José M López-Novoa, Xosé R Bustelo, Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction Nature Medicine. ,vol. 12, pp. 841- 845 ,(2006) , 10.1038/NM1426